US Edition
Published • loading... • Updated
NICE Set to Review Evidence on Two Pioneering Alzheimer’s Drugs
Summary by thecareruk.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
NICE Set to Review Evidence on Two Pioneering Alzheimer’s Drugs
The UK’s medicines cost watchdog is to take a fresh look at two high-profile Alzheimer’s treatments after successful appeals from their manufacturers. National Institute for Health and Care Excellence (NICE) confirmed it will revisit its draft guidance on donanemab and lecanemab, both of which were approved for use in the UK in 2024 but have yet to be made available on the NHS. The drugs were previously rejected for routine NHS use after NICE co…
Lecanemab is considered a promising treatment in the fight against Alzheimer's disease. However, the Federal Joint Committee sees no additional benefit. Doctors in Augsburg have had positive experiences with it.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
